{"entity":{"id":"gyala-therapeutics","kind":"company","name":"Gyala Therapeutics","aka":[],"tldr":"Gyala Therapeutics develops CAR-T cell therapy, in which a patient's own immune cells are modified to attack leukaemia. Its first product targets a protein called CD84 and is in an early trial in acute myeloid leukaemia and T-cell acute lymphoblastic leukaemia that has come back or not responded.","summary":"Gyala Therapeutics was founded in 2020 as a spin-off of Hospital Clinic Barcelona and the IDIBAPS research institute, according to the company. GYA01 is a CAR-T cell therapy targeting CD84. Spain's AEMPS authorised a phase 1/2a, open-label, single-arm trial (NCT07471789) in relapsed or refractory acute myeloid leukaemia and T-cell acute lymphoblastic leukaemia, with recruitment announced in February 2026 at Hospital La Fe in Valencia and Hospital Clinic Barcelona. In October 2024 the company announced 3 million euros from CDTI Innovation (Innvierte programme), Nara Capital and Invivo Partners, following a 1.5 million euro seed round in 2020. Its first registered cancer trial, NCT07471789, was posted on ClinicalTrials.gov in March 2026.","asOf":"2026-10-29","links":[{"label":"Official website","url":"https://gyalatx.com/"},{"label":"Gyala: phase 1/2a trial of GYA01 begins (February 2026)","url":"https://gyalatx.com/gyala-therapeutics-initiates-phase-i-iia-clinical-trial-of-a-car-t-cell-therapy-for-acute-leukemias-with-limited-treatment-options/"}],"tags":[],"related":[],"cancers":["aml","all-leukemia"],"sections":["cell-therapy","immunotherapy"],"technologies":["car-t"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct07471789"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["The website does not state a headquarters address; Barcelona is inferred from the spin-off from Hospital Clinic Barcelona and IDIBAPS.","The company's own URLs use GYA001 and its text GYA01 for the same product.","CD84 has no OnCo target record and is named in text only.","Company website and releases read on 29 October 2026."],"hq":"Barcelona","country":"ES","companyType":"cell-therapy","website":"https://gyalatx.com/","founded":2020,"stage":"startup","investors":[],"funding":[{"round":"Venture round","year":2024,"source":"https://gyalatx.com/gyala-therapeutics-raises-e3-million-to-advance-car-t-therapy-gya001-into-clinical-development/","note":"3 million euros from CDTI Innovation (Innvierte), Nara Capital and Invivo Partners; the round is not named. No US dollar figure stated."},{"round":"Seed","year":2020,"source":"https://gyalatx.com/gyala-therapeutics-raises-e3-million-to-advance-car-t-therapy-gya001-into-clinical-development/","note":"1.5 million euros, as mentioned in the October 2024 release."}]},"route":"/companies/gyala-therapeutics/","neighbours":{"cancer":[{"id":"all-leukemia","kind":"cancer","name":"Acute lymphoblastic leukaemia","route":"/cancers/all-leukemia/"},{"id":"aml","kind":"cancer","name":"Acute myeloid leukaemia","route":"/cancers/aml/"}],"section":[{"id":"cell-therapy","kind":"section","name":"Cell Therapy","route":"/fronts/cell-therapy/"},{"id":"immunotherapy","kind":"section","name":"Immunotherapy","route":"/fronts/immunotherapy/"}],"technology":[{"id":"car-t","kind":"technology","name":"CAR-T cell therapy","route":"/technologies/car-t/"}],"trial":[{"id":"nct07471789","kind":"trial","name":"Safety and Efficacy of GYA01 (CART84) in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and Acute Lymphoblastic T Leukemia Patients (T-ALL).","route":"/trials/nct07471789/"}]}}